Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 56 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: ACC Clear all
Completed No phase listed Observational

Genetic Analysis of Left-Right Axis Formations

NCT00341133
View directory record Official record
Conditions
Congenital Heart Disease
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
Not listed
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 21, 2026, 10:23 AM EDT
Recruiting Phase 2 Interventional

PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma

NCT05286814
View directory record Official record
Conditions
Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc), Intrahepatic Bile Duct Cancer, Colorectal Neoplasms, Colorectal Cancer, Cholangiocarcinoma, Bile Duct Neoplasms, Bile Duct Cancer, Adrenocortical Carcinoma (ACC), Adrenal Cortical Carcinoma, Adrenal Gland Cancer, Adrenal Gland Neoplasms, Adrenal Cortex Neoplasms
Interventions
Dexamethasone, PDS01ADC, Intera 3000 Hepatic Artery Infusion Pump (HAIP), Floxuridine
Drug · Device
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 21, 2026, 10:23 AM EDT
Completed Phase 4 Interventional Results available

Endocrine Dysfunction and Growth Hormone Deficiency in Children With Optic Nerve Hypoplasia

NCT00140413
View directory record Official record
Conditions
Growth Hormone Deficiency, Septo-Optic Dysplasia, Hypopituitarism
Interventions
Nutropin AQ
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
Up to 5 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 1, 2015 · Synced Oct 21, 2026, 10:23 AM EDT
Completed Not applicable Interventional Results available

Compassionate Use of Brontictuzumab for Adenoid Cystic Carcinoma (ACC)

NCT02662608
View directory record Official record
Conditions
Adenoid Cystic Carcinoma
Interventions
Brontictuzumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 21, 2026, 10:23 AM EDT
Terminated Phase 2 Interventional Results available

IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery

NCT00778817
View directory record Official record
Conditions
Recurrent Adrenocortical Carcinoma, Stage III Adrenocortical Carcinoma, Stage IV Adrenocortical Carcinoma
Interventions
IMC-A12, mitotane
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
8
States / cities
Los Angeles, California • Chicago, Illinois • Decatur, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2014 · Synced Oct 21, 2026, 10:23 AM EDT
Completed No phase listed Observational

Patient and Provider Assessment of Lipid Management Registry

NCT02341664
View directory record Official record
Conditions
Hyperlipidemia, Hypercholesterolemia, Cardiovascular Disease, Diabetes, Chronic Kidney Disease (CKD), Hypertension, Smoking, Myocardial Infarction (MI), Unstable Angina, Angina, Coronary Artery Disease (CAD), Stroke, Transient Ischemic Attack (TIA), Carotid Stenosis, Peripheral Arterial Disease, Atherosclerosis, Claudication
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
7,658 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
14
States / cities
Little Rock, Arkansas • San Pedro, California • Ventura, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Oct 21, 2026, 10:23 AM EDT
Not yet recruiting Phase 1 Interventional

Bioengineered Penile Tissue Constructs for Irreversibly Damaged Penile Corpora

NCT03463239
View directory record Official record
Conditions
Urologic Diseases, Male Urogenital Diseases, Penile Diseases, Corpus Callosum Malformation, Corpora Cavernosa; Inflammation, Trauma Injury
Interventions
Autologous tissue engineered corpora
Biological
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 60 Years · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 21, 2026, 10:23 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Study of the Genetic Analysis of Brain Disorders

NCT00645645
View directory record Official record
Conditions
Holoprosencephaly
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
1 Month and older
Enrollment
5,735 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Oct 21, 2026, 10:23 AM EDT
Completed Not applicable Interventional Results available

Micra Transcatheter Pacing Study

NCT02004873
View directory record Official record
Conditions
Class I or II Indication for Implantation of a Single Chamber Ventricular Pacemaker According to ACC/AHA/HRS 2001 Guidelines and Any National Guidelines
Interventions
Micra Pacemaker Implant
Device
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
18 Years and older
Enrollment
744 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
30
States / cities
La Jolla, California • Los Angeles, California • New Haven, Connecticut + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Oct 21, 2026, 10:23 AM EDT
Completed No phase listed Observational

Efficacy of the CMI Magnetocardiograph in Diagnosing Acute Coronary Syndromes in Patients Presenting With High Risk Unstable Angina.

NCT00169975
View directory record Official record
Conditions
Myocardial Ischemia
Interventions
Magnetocardiograph
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 18, 2011 · Synced Oct 21, 2026, 10:23 AM EDT
Completed Phase 2 Interventional

Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC)

NCT00215202
View directory record Official record
Conditions
Nonresectable Adrenocortical Carcinoma
Interventions
Iressa (ZD1839)
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
4
States / cities
Louisville, Kentucky • Boston, Massachusetts • Lebanon, New Hampshire + 1 more
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Oct 21, 2026, 10:23 AM EDT
Completed Phase 2 Interventional Results available

A Study Of AL101In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations

NCT03691207
View directory record Official record
Conditions
Adenoid Cystic Carcinoma
Interventions
AL101
Drug
Lead sponsor
Ayala Pharmaceuticals, Inc,
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
10
States / cities
Los Angeles, California • Aurora, Colorado • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Oct 21, 2026, 10:23 AM EDT
Completed Phase 2 Interventional Results available

Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma

NCT03990571
View directory record Official record
Conditions
Metastatic Adenoid Cystic Carcinoma, Progressive Disease, Recurrent Adenoid Cystic Carcinoma
Interventions
Avelumab, Axitinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 18, 2024 · Synced Oct 21, 2026, 10:23 AM EDT
Active, not recruiting Phase 1 Interventional

Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)

NCT06462183
View directory record Official record
Conditions
Adenoid Cystic Carcinoma, Colorectal Cancer
Interventions
RGT-61159, lenvatinib
Drug
Lead sponsor
Rgenta Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 21, 2026, 10:23 AM EDT
Active, not recruiting No phase listed Observational

Optimal Methods of Disease Progression and Survival Analysis in Children and Adults Patients With Adrenocortical Cancer (ACC)

NCT04358107
View directory record Official record
Conditions
Adrenocortical Carcinoma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 21, 2026, 10:23 AM EDT
Completed No phase listed Observational

Study of the Experiences and Needs of Parents Continuing a Pregnancy Following a Prenatal Diagnosis of Holopresencephaly

NCT00005016
View directory record Official record
Conditions
Holoprosencephaly
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 21, 2026, 10:23 AM EDT
Recruiting No phase listed Observational

Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)

NCT05237934
View directory record Official record
Conditions
Neuroendocrine Tumors, Carcinoma, Neuroendocrine
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 21, 2026, 10:23 AM EDT
Not listed Not applicable Interventional

Baxter: Actifuse SHAPE vs DBX in ACC

NCT02005081
View directory record Official record
Conditions
Cervical Spine Degenerative Disease Nos, Cervical Spondylosis With Myelopathy
Interventions
Actifuse SHAPE, Autograft with Demineralized Bone Matrix
Device
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 9, 2013 · Synced Oct 21, 2026, 10:23 AM EDT
Completed No phase listed Observational

Understanding the Burden of ACC Through the Eyes of Patients

NCT04706845
View directory record Official record
Conditions
Adenoid Cystic Carcinoma
Interventions
Not listed
Lead sponsor
Ayala Pharmaceuticals, Inc,
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Eagan, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 29, 2023 · Synced Oct 21, 2026, 10:23 AM EDT
Completed Phase 2 Interventional Results available

Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane, and Tariquidar to Treat Adrenocortical Cancer

NCT00071058
View directory record Official record
Conditions
Adrenal Cortex Neoplasms
Interventions
XR9576 (Tariquidar)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 18, 2012 · Synced Oct 21, 2026, 10:23 AM EDT
Completed Phase 2 Interventional Results available

Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery

NCT00848016
View directory record Official record
Conditions
Recurrent Adrenocortical Carcinoma, Stage III Adrenocortical Carcinoma, Stage IV Adrenocortical Carcinoma
Interventions
R-(-)-gossypol acetic acid
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Los Angeles, California • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 7, 2014 · Synced Oct 21, 2026, 10:23 AM EDT
Recruiting Phase 1Phase 2 Interventional

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

NCT03556228
View directory record Official record
Conditions
Head and Neck Carcinoma, Adenoid Cystic Carcinoma, Lung Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer, Mesothelioma, Esophageal Cancer, Any Solid Tumors Progressed After a Prior Immunotherapy, Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma HNSCC, Salivary Gland Carcinomas, Head and Neck Cancers - Salivary Gland, Head and Neck Cancers - Nasopharyngeal, Head and Neck Cancers - Throat, Small Cell Lung Cancer ( SCLC ), Lung Cancer (Locally Advanced or Metastatic), Head and Neck Cancers - Tonsils, Head and Neck Cancers Hypopharynx, Head and Neck Cancers Larynx, Head and Neck Cancers Lip, Head and Neck Cancers Nasopharynx, Head and Neck Cancers Oral Cavity, Head and Neck Cancers, Head and Neck Cancers Oropharynx, Head and Neck Cancers Trachea
Interventions
VMD-928 100 mg Tablet, VMD-928 Tablet and Pembrolizumab (200 mg)
Drug
Lead sponsor
VM Oncology, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
14
States / cities
Santa Rosa, California • Hartford, Connecticut • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 21, 2026, 10:23 AM EDT
Terminated Phase 1 Interventional

A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors

NCT05194072
View directory record Official record
Conditions
Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms, Triple Negative Breast Neoplasms, HER2 Negative Breast Neoplasms, Hormone Receptor Positive Breast Neoplasms, Endometrial Neoplasms, Carcinoma, Non-Small-Cell Lung, Cholangiocarcinoma, Gallbladder Carcinoma, Adenoid Cystic Carcinoma
Interventions
Felmetatug Vedotin, Pembrolizumab
Drug
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
22
States / cities
Aurora, Colorado • Denver, Colorado • Celebration, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 21, 2026, 10:23 AM EDT
Recruiting No phase listed Observational

STS/ACC Transcatheter Valve Therapy Registry (TVT Registry)

NCT01737528
View directory record Official record
Conditions
Aortic Valve Stenosis
Interventions
Transcatheter Aortic Valve Replacement
Procedure
Lead sponsor
The Society of Thoracic Surgeons
Other
Eligibility
18 Years and older
Enrollment
16,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2035
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 25, 2022 · Synced Oct 21, 2026, 10:23 AM EDT